Achieving growth through strategic alliances with global biopharmaceuticals

HuMab is launching both “First-in-class” and ”Best-in-class” antibody therapeutics in the market through strategic alliances with global pharmaceutical companies, providing the best therapeutic solutions for medical unmet needs in clinical interventions.

Fast antibody discovery using our proprietary SynThese™ transgenic mouse platform assures mutual benefits for the future business partners by delivering fully potentiated mature antibody therapeutics with the highest success rate in clinical trials within the shortest period of R&D process.